BioCentury | Mar 13, 2020
Management Tracks

Camerini steps down as Cosmo CSO; plus CytoDyn, G1 Therapeutics, Flexion and Clearside

Gastrointestinal disorders company Cosmo Pharmaceuticals N.V. (SIX:COPN) said CSO Roberto Camerini has resigned. Luigi Moro, who was Cosmo's CSO from 1999-2019, will come out of retirement to serve as interim CSO until a permanent successor...
BC Extra | Oct 30, 2019
Company News

Management tracks: Vectura, Editas, Assembly, Camp4, Tempus, Passage Bio, Boundless Bio and Prometheus

Inhaled drug delivery platform company Vectura Group plc (LSE:VEC) hired Will Downie as CEO and executive director, effective Nov. 7. CFO Paul Fry has been serving as interim CEO since James Ward-Lilley stepped down in...
BC Innovations | Mar 15, 2019
Product Development

Fresh AIMMs for elite responders

AIMM Therapeutics B.V.’s elite responder platform has identified mAbs that distinguish tumor and healthy cells based on protein modifications. The company is one of a handful of players mining the immune systems of cancer patients...
BioCentury | Jan 12, 2019
Finance

We all fall down

After an exuberant third quarter that put biotech indexes near their 2015 highs, all market cap tiers fell in 4Q18, eliminating the first nine month’s gains and losing $291.2 billion in aggregate value. Median losses...
BioCentury | Jan 5, 2019
Finance

Ready to launch

  The proposed $74 billion takeout of Celgene Corp. by Bristol-Myers Squibb Co. will not shift buysider attention away from upcoming and maturing drug launches heading into 2019, with plenty to track following a record...
BC Week In Review | Nov 30, 2018
Clinical News

FDA approves traveler's diarrhea drug from Cosmo

FDA approved Aemcolo rifamycin from Cosmo Pharmaceuticals N.V. (SIX:COPN) to treat travelers' diarrhea caused by non-invasive strains of Escherichia coli . The company said it will launch the drug next quarter. Aemcolo is a broad-spectrum, semisynthetic,...
BioCentury | Oct 6, 2018
Finance

Seeking validation

The final stretch of the year offers clinical catalysts and early launch data that could validate investments in hot immuno-oncology targets and large untapped markets. Late-stage readouts from Vertex Pharmaceuticals Inc. in cystic fibrosis and...
BioCentury | Jun 30, 2018
Finance

Eyes on launches

The annual summer slowdown isn’t restricted to just the stock market this year, as the clinical catalyst calendar also appears to be on holiday in 3Q18. Buysiders are therefore turning their attention to a spate...
BC Week In Review | May 25, 2018
Clinical News

FDA accepts NDA for Cosmo's antibiotic

Cosmo Pharmaceuticals N.V. (SIX:COPN) said FDA accepted and granted Priority Review to an NDA for Aemcolo (Rifamycin SV MMX) to treat travelers’ diarrhea. The PDUFA date is Nov. 16. Aemcolo is a broad-spectrum, semisynthetic, oral...
BC Extra | May 18, 2018
Company News

FDA accepts NDA for Cosmo's antibiotic

Cosmo Pharmaceuticals N.V. (SIX:COPN) said FDA accepted and granted Priority Review to an NDA for Aemcolo (Rifamycin SV MMX) to treat travelers’ diarrhea. The PDUFA date is Nov. 16. Aemcolo is a broad-spectrum, semisynthetic, oral...
Items per page:
1 - 10 of 166
BioCentury | Mar 13, 2020
Management Tracks

Camerini steps down as Cosmo CSO; plus CytoDyn, G1 Therapeutics, Flexion and Clearside

Gastrointestinal disorders company Cosmo Pharmaceuticals N.V. (SIX:COPN) said CSO Roberto Camerini has resigned. Luigi Moro, who was Cosmo's CSO from 1999-2019, will come out of retirement to serve as interim CSO until a permanent successor...
BC Extra | Oct 30, 2019
Company News

Management tracks: Vectura, Editas, Assembly, Camp4, Tempus, Passage Bio, Boundless Bio and Prometheus

Inhaled drug delivery platform company Vectura Group plc (LSE:VEC) hired Will Downie as CEO and executive director, effective Nov. 7. CFO Paul Fry has been serving as interim CEO since James Ward-Lilley stepped down in...
BC Innovations | Mar 15, 2019
Product Development

Fresh AIMMs for elite responders

AIMM Therapeutics B.V.’s elite responder platform has identified mAbs that distinguish tumor and healthy cells based on protein modifications. The company is one of a handful of players mining the immune systems of cancer patients...
BioCentury | Jan 12, 2019
Finance

We all fall down

After an exuberant third quarter that put biotech indexes near their 2015 highs, all market cap tiers fell in 4Q18, eliminating the first nine month’s gains and losing $291.2 billion in aggregate value. Median losses...
BioCentury | Jan 5, 2019
Finance

Ready to launch

  The proposed $74 billion takeout of Celgene Corp. by Bristol-Myers Squibb Co. will not shift buysider attention away from upcoming and maturing drug launches heading into 2019, with plenty to track following a record...
BC Week In Review | Nov 30, 2018
Clinical News

FDA approves traveler's diarrhea drug from Cosmo

FDA approved Aemcolo rifamycin from Cosmo Pharmaceuticals N.V. (SIX:COPN) to treat travelers' diarrhea caused by non-invasive strains of Escherichia coli . The company said it will launch the drug next quarter. Aemcolo is a broad-spectrum, semisynthetic,...
BioCentury | Oct 6, 2018
Finance

Seeking validation

The final stretch of the year offers clinical catalysts and early launch data that could validate investments in hot immuno-oncology targets and large untapped markets. Late-stage readouts from Vertex Pharmaceuticals Inc. in cystic fibrosis and...
BioCentury | Jun 30, 2018
Finance

Eyes on launches

The annual summer slowdown isn’t restricted to just the stock market this year, as the clinical catalyst calendar also appears to be on holiday in 3Q18. Buysiders are therefore turning their attention to a spate...
BC Week In Review | May 25, 2018
Clinical News

FDA accepts NDA for Cosmo's antibiotic

Cosmo Pharmaceuticals N.V. (SIX:COPN) said FDA accepted and granted Priority Review to an NDA for Aemcolo (Rifamycin SV MMX) to treat travelers’ diarrhea. The PDUFA date is Nov. 16. Aemcolo is a broad-spectrum, semisynthetic, oral...
BC Extra | May 18, 2018
Company News

FDA accepts NDA for Cosmo's antibiotic

Cosmo Pharmaceuticals N.V. (SIX:COPN) said FDA accepted and granted Priority Review to an NDA for Aemcolo (Rifamycin SV MMX) to treat travelers’ diarrhea. The PDUFA date is Nov. 16. Aemcolo is a broad-spectrum, semisynthetic, oral...
Items per page:
1 - 10 of 166